Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypoglycemia - Overview
Hypoglycemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoglycemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoglycemia - Companies Involved in Therapeutics Development
Adocia SAS
Avolynt Inc
Covis Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
LATITUDE Pharmaceuticals Inc
Protomer Technologies Inc
Rezolute Inc
USV Pvt Ltd
Zealand Pharma AS
Zosano Pharma Corp
Zucara Therapeutics Inc
Hypoglycemia - Drug Profiles
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVO-3235 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rescue-G - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News & Press Releases
Feb 23, 2021: Eiger announces publication of phase 2 PREVENT study results of Avexitide in post-bariatric hypoglycemia in Jourl of Clinical Endocrinology & Metabolism
Dec 15, 2020: Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)
Nov 02, 2020: Zucara Therapeutics expands ZT-01 development program to type 2 diabetes
Sep 29, 2020: Zucara Therapeutics doses first subject in phase 1 trial of ZT-01
Jun 14, 2020: Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association
May 22, 2020: Zealand Pharma announces FDA acceptance of new drug application for the dasiglucagon HypoPal rescue pen for treatment of severe hypoglycemia
Mar 31, 2020: Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal Rescue Pen for treatment of severe hypoglycemia
Mar 30, 2020: Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery
Sep 26, 2019: Zealand reports results of paediatric Phase 3 trial for hypoglycaemia
Jun 17, 2019: Eiger announces breakthrough therapy desigtion granted by FDA for Avexitide for treatment of Post-Bariatric Hypoglycemia (PBH)
Jun 10, 2019: Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)
May 14, 2019: Zealand announces confirmatory Phase III results in hypoglycaemia
Mar 25, 2019: Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
Mar 07, 2019: Zealand Pharma begins dosing in Phase III trial for CHI
Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Hypoglycemia, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Top Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Hypoglycemia, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Hypoglycemia - Pipeline by Adocia SAS, 2021
Hypoglycemia - Pipeline by Avolynt Inc, 2021
Hypoglycemia - Pipeline by Covis Pharmaceuticals Inc, 2021
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, 2021
Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, 2021
Hypoglycemia - Pipeline by Protomer Technologies Inc, 2021
Hypoglycemia - Pipeline by Rezolute Inc, 2021
Hypoglycemia - Pipeline by USV Pvt Ltd, 2021
Hypoglycemia - Pipeline by Zealand Pharma AS, 2021
Hypoglycemia - Pipeline by Zosano Pharma Corp, 2021
Hypoglycemia - Pipeline by Zucara Therapeutics Inc, 2021
Hypoglycemia - Dormant Projects, 2021
Hypoglycemia - Discontinued Products, 2021